[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.226.244.70. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Letters
March 7, 2012

Prescription Drug Monitoring Programs

Author Affiliations

Author Affiliations: Stanford University School of Medicine, Stanford, California (Mr Yokell) (myokell@Stanford.edu); and Warren Alpert Medical School of Brown University, Providence, Rhode Island (Drs Green and Rich).

JAMA. 2012;307(9):912-913. doi:10.1001/jama.307.9.912-b

To the Editor: The Commentary by Drs Gugelmann and Perrone1 highlights the important role of prescription monitoring programs in the struggle against opioid misuse in the United States. Although the authors emphasized the uncertain efficacy of these programs in reducing opioid-related morbidity and mortality, we believe there are additional applications for these programs and alternate ways to assess their overall effect.

×